Neuralink has responded to claims of inhumane treatment during the animal testing phases of various company products, stating that animal welfare is a priority. “At Neuralink, we are absolutely committed to working with animals in the most humane and ethical way possible.”
Last week, reports surfaced of a lawsuit against the University of California at Davis from the Physicians Committee of Responsible Medicine (PCRM). The suit claims that the facility “failed to provide dying monkeys with adequate veterinary care, used an unapproved substance known as “Bioglue” that killed monkeys by destroying portions of their brains, and failed to provide for the psychological well-being of monkeys assigned to the experiment.” Earlier today, Teslarati reported an extensive timeline of events from the beginning of the partnership between UC Davis and Neuralink to the most recent developments, which include the potential of videos and photographs of the animals involved in the testing. Teslarati obtained several copies of veterinarian records from autopsies of some monkeys used in the experiments.
Neuralink is now responding to the various claims of animal abuse in a lengthy statement that outlines the past, present, and future developments of Neuralink trials. The company maintains that all animals are treated respectfully and ethically.
EXCLUSIVE: Neuralink dragged into humane testing lawsuit – Timeline of Events
Neuralink ended its partnership with UC Davis in November 2020, just two months after PCRM sent a California Public Records request for information regarding the Neuralink trials. The request is eventually denied in accordance with California State Code 6255(a), which says that the Agency “shall justify withholding any record by demonstrating that the record in question is exempt under express provisions of this chapter or that on the facts of the particular case the public interest served by not disclosing the record clearly outweighs the public interest served by disclosure of the record.”
Neuralink took several of the monkeys back to its testing facilities in Northern California for in-house experiments. “Once construction of our in-house facility was completed, we were able to bring some unimplanted macaques from UC Davis with us to Neuralink. This included Pager, who would later be implanted with our Neuralink device and go on to achieve outstanding brain-computer interface performance, while freely behaving and unrestrained, as demonstrated in the Monkey MindPong video,” the company’s official response said. “While the facilities and care at UC Davis did and continue to meet federally mandated standards, we absolutely wanted to improve upon these standards as we transitioned animals to our in-house facilities.”
Neuralink says that “no injuries occurred at any time to animals housed at UC Davis” while the tests were ongoing. The company admits several animals were euthanized for research purposes, but they were done under controlled circumstances:
“The initial work from these procedures allowed us to develop our novel surgical and robot procedures, establishing safer protocols for subsequent survival surgeries. Survival studies then allowed us to test the function of different generations of implanted devices as we refined them towards human use. The use of every animal was extensively planned and considered to balance scientific discovery with the ethical use of animals. As part of this work, two animals were euthanized at planned end dates to gather important histological data, and six animals were euthanized at the medical advice of the veterinary staff at UC Davis. These reasons included one surgical complication involving the use of the FDA-approved product (BioGlue), one device failure, and four suspected device-associated infections, a risk inherent with any percutaneous medical device. In response we developed new surgical protocols and a fully implanted device design for future surgeries.”
Interestingly, PCRM said in a press release that “BioGlue” is an unapproved substance. FDA documents obtained by Teslarati show that BioGlue was approved for use in 2001, but the agency also included a warning of potential side effects when BioGlue is applied to the phrenic nerve. Application of BioGlue to this area in animals can cause acute nerve injury. Additionally, “BioGlue application to the surface of the heart can cause coagulation necrosis that extends into the myocardium, which could reach underlying conduction tissue and may cause acute, focal sinoatrial node degeneration,” the documents said. Five pigs were tested during initial animal experimentation while the FDA was determining BioGlue’s safety. All five pigs survived to the designated observation time.
Neuralink details humane animal treatment during Link v0.9 testing
Presently, the animals involved in Neuralink testing are housed at the company’s 6,000-square-foot facility that houses farm animals and rhesus macaques. The company takes care of the animals from the time they enter the facility to the time they leave, even detailing an animal’s process for “retirement:”
“Can we release the animals that regularly choose not to participate or who have completed their contribution to the study? Yes! We opted to retire animals at the conclusion of their projects. We retired several macaques to a sanctuary last March because they consistently chose to spend their day swimming in their pools, foraging, and relaxing in their hammocks rather than attending the game we presented to them. Their brand new enclosures and sanctuary costs were fully funded by Neuralink.”
Moving forward, Neuralink says it is always working to improve the current standards for animal well-being. “We also look forward to a day where animals are no longer necessary for medical research. Yet our society currently relies on medical breakthroughs to cure diseases, prevent the spread of viruses, and create technology that can change how people are able to interact with the world. However, if animals must be used in research in the meantime, their lives and experiences should be as vital and naturalistic as possible. We will always strive to surpass the industry standard and never stop asking ourselves: “Can we do better for the animals?”, and never forget it is a privilege to work with animals in research. It is our responsibility as caretakers to ensure that their experience is as peaceful and frankly, as joyful as possible.”
Neuralink’s complete statement is available here.
I’d love to hear from you! If you have any comments, concerns, or questions, please email me at joey@teslarati.com. You can also reach me on Twitter @KlenderJoey, or if you have news tips, you can email us at tips@teslarati.com.
A new report claims that Apple is in the process of developing what would be the missing link for Tesla to get CarPlay.
Apple and Tesla have been reportedly working together for some time to give Tesla owners the opportunity to utilize CarPlay within their vehicles. While many owners are more than happy with Tesla’s in-house UI, which is seamless, effective, and smooth, some still want CarPlay, which does have its advantages.
A report from 9to5Mac now states that a new CarPlay technology that was highlighted during the Worldwide Developers Conference (WWDC) would potentially be the bridge between Tesla and Apple. With the addition of a feature known as “Route Sharing,” which gives a navigation app the ability to share routing data with the vehicle, Tesla would be able to launch CarPlay in its vehicles, the report states.
CarPlay has not been a priority for Tesla because it has done extremely well with its in-house UI, but some drivers are just used to it. Additionally, it could improve Tesla’s subpar Navigation or offer improved app capabilities, especially with iMessage.
Route Sharing is an intended addition to CarPlay’s iteration in iOS 26.4, which was released in March:
The addition of CarPlay would undoubtedly be welcome, but at the same time, it seems like Tesla realizes it is not of the utmost priority. There are so many things that Tesla is working on currently within its own vehicles, especially attempting to solve self-driving.
Back in February, Bloomberg had reported that Tesla was still working on bringing CarPlay to its vehicles, but it had not due to app compatibility issues and incredibly low adoption rates of iOS 26.
This bottleneck could buy Tesla the proper amount of time to develop CarPlay for its vehicles. It would be a welcome addition, and could be brought on with either the Summer or Fall 2026 Software Updates.
Tesla deliveries got a big boost in expectations from Wall Street firm Goldman Sachs, who believes the company will report some stronger-than-expected numbers when the second quarter comes to an end in the coming weeks.
Goldman Sachs has raised its vehicle delivery forecast for Tesla (NASDAQ: TSLA) in the second quarter of 2026, signaling growing confidence in the electric vehicle leader’s near-term momentum despite mixed market signals. Analyst Mark Delaney lifted the bank’s Q2 estimate to 420,000 units from a previous 405,000, surpassing the Visible Alpha consensus estimate of 400,000.
The upward revision stems from stronger-than-expected sales data across key regions. Europe stands out with projected year-over-year growth of 85-90 percent, driven by robust demand for Tesla’s Model Y and refreshed offerings. China posted high single-digit gains, while markets like South Korea and Australia also contributed positive momentum. These gains help offset mid-teens declines in U.S. deliveries through May, where broader EV market headwinds and competition persist.
Goldman extended its optimism to the full year, increasing its 2026 delivery projection to 1.73 million vehicles from 1.72 million. Longer-term forecasts remain unchanged, with 1.88 million units expected in 2027 and 1.96 million in 2028. The bank also nudged its 2026 earnings-per-share estimate higher to $1.35 from $1.30, reflecting anticipated margin benefits from higher volumes and operational efficiencies.
Despite these positive adjustments, Goldman maintained its Neutral rating and $375 price target on Tesla shares. At current trading levels near $411, the stock sits about 8-9 percent above the target, highlighting ongoing valuation concerns even as delivery momentum builds. Tesla’s Q1 2026 deliveries totaled 358,023 units, setting a baseline for recovery expectations in the current period.
This update arrives as Tesla prepares to report official Q2 figures shortly after June 30. Investors and analysts will closely watch not only headline delivery numbers but also regional breakdowns, average selling prices, and progress on energy storage deployments and autonomous technology initiatives.
The move by Goldman Sachs underscores a broader narrative for Tesla: while legacy auto markets face softening demand and tariff uncertainties, Tesla’s global footprint and product pipeline provide resilience. Europe’s surge reflects pent-up demand and policy support for EVs, while China’s steady growth highlights Tesla’s competitive positioning against local rivals.
Tesla still has its work cut out for it, including U.S. price sensitivity and intensifying competition. Yet Goldman’s revision adds to a series of analyst notes suggesting Q2 could mark a turning point. As Tesla pushes toward higher production rates at facilities in Fremont, Shanghai, and Berlin, sustained execution will be key to validating these higher forecasts.
We have said numerous times that deliveries are becoming a less important metric in the grand scheme of things, as AI truly takes precedence in the company’s thesis.
For Tesla bulls, the Goldman note reinforces faith in underlying demand trends. For skeptics, the unchanged rating serves as a reminder that delivery beats alone may not immediately resolve valuation debates in a high-interest-rate environment. Tesla’s stock reaction will likely hinge on the official numbers and management commentary in the coming weeks.
SpaceX has exercised its option to acquire Cursor, the innovative AI coding company, in an all-stock transaction valued at $60 billion. The deal, announced on June 16, marks a significant step in SpaceX’s expansion into advanced artificial intelligence, building on months of close collaboration between the companies.
Cursor, officially operated by Anysphere, Inc., is an AI-native code editor and coding agent designed to transform software development. Founded in 2022 by a group of MIT graduates in San Francisco, Cursor builds on the familiar foundation of Visual Studio Code but integrates powerful AI capabilities directly into the core experience.
Unlike traditional code editors or simple extensions, Cursor functions as a full “coding agent” that turns natural-language instructions into actionable code.
SpaceX has exercised the option to acquire @cursor_ai in an all-stock transaction with the goal of building the world’s most useful AI models.
For the past few months, SpaceXAI has been jointly training a model with Cursor, which will be released in Cursor and Grok Build soon.… https://t.co/X5mepgXgjJ
— SpaceX (@SpaceX) June 16, 2026
Developers interact with Cursor through features like its Composer agent, which can search entire codebases, edit multiple files, run terminal commands, debug issues, and complete complex multi-step programming tasks autonomously.
Users describe high-level goals, such as “build a scalable API endpoint with authentication,” and the AI plans, implements, tests, and refines the solution while the human oversees decisions. Additional tools include advanced autocomplete (Tab), context-aware chat, and infrastructure for handling billions of daily requests.
The platform has gained considerable traction, surpassing $3 billion in annual recurring revenue by early 2026 and earning adoption by over half of the Fortune 500 companies. Its agentic approach accelerates development dramatically, allowing engineers to focus on architecture and creativity rather than repetitive coding.
The acquisition integrates Cursor’s leading product, expert team of roughly 300 engineers, and distribution network among top software developers with SpaceX’s unparalleled computational resources. SpaceX’s Colossus supercomputer, equivalent to a million H100 GPUs, has already powered joint training of next-generation models. These models are expected to launch soon within Cursor and SpaceX’s Grok Build environment.
This combination positions SpaceX to develop the world’s most capable AI systems for coding and knowledge work. Access to Cursor’s real-world usage data from millions of professional developers provides unparalleled feedback loops for model improvement. Training on Colossus enables rapid iteration on massive datasets, potentially creating AI that outperforms current leaders in reliability, context handling, and complex reasoning.
For SpaceX, the benefits extend far beyond software tools. Rocket engineering, satellite constellation management, autonomous flight systems, and Starship development involve millions of lines of highly specialized, safety-critical code.
Cursor’s AI agents, supercharged by proprietary models trained on SpaceX’s domain expertise, could slash development timelines, reduce errors, and enable faster innovation cycles. This vertical integration of AI tooling strengthens SpaceX’s competitive edge in both aerospace and the broader AI race, complementing its xAI initiatives.
The deal reflects the exploding value of AI-native developer platforms. By owning Cursor outright, SpaceX secures a strategic talent pool and product pipeline that will accelerate internal projects while potentially offering enhanced tools to the wider engineering community. As AI continues reshaping software creation, this acquisition underscores SpaceX’s commitment to leveraging cutting-edge technology for ambitious goals, from Mars colonization to global connectivity.
Apple is developing the missing link for Tesla to get CarPlay: report
Tesla deliveries get a big boost in expectations from Wall Street
